New study aims to find best dose of privigen for kids with nerve disorder
NCT ID NCT03684018
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at two different doses of a medicine called Privigen in children aged 2 to 17 with a nerve disease called CIDP. The goal is to see which dose better prevents the disease from getting worse. About 30 children will take part, and the study is currently recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akron Children's Hospital
WITHDRAWNAkron, Ohio, 44647, United States
-
Children's Hospital of Los Angeles
WITHDRAWNLos Angeles, California, 90027, United States
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Children's Specialty Group
COMPLETEDNorfolk, Virginia, 23507, United States
-
Le Bonheur Children's Hospital
WITHDRAWNMemphis, Tennessee, 38105, United States
-
Neurology Rare Disease Center
RECRUITINGFlower Mound, Texas, 75028, United States
-
Phoenix Children's Hospital
COMPLETEDPhoenix, Arizona, 85016, United States
-
Seattle Children's Hospital
RECRUITINGSeattle, Washington, 98105, United States
-
University of Iowa Hospitals and Clinics
WITHDRAWNIowa City, Iowa, 52242-1009, United States